TL;DR: Retatrutide (LY3437943) is an investigational unimolecular triple agonist of the GIP, GLP-1, and glucagon receptors, developed by Eli Lilly. Phase 2 randomized controlled trials published in 2023 documented up to 24.2% mean body weight reduction at 48 weeks in adults with obesity, and significant HbA1c and body weight improvements in type 2 diabetes. Retatrutide is not FDA approved, has no authorized dosing protocol for human use, and is currently in Phase 3 trials. All evidence cited here is from controlled clinical trial settings and does not constitute guidance for any individual use.
Investigational Status Disclaimer: This article is for educational and research reference purposes only. Retatrutide is an investigational compound that is not approved by the FDA for any therapeutic use. It is in ongoing Phase 3 clinical trials as of 2026. This content does not constitute medical advice, does not recommend or endorse human administration of any compound, and does not describe protocols for personal use. All data described below refer to published clinical trial findings. For adults 21+ with a research interest only.
What Is Retatrutide? Definition and Development Context
Retatrutide (also known by its development code LY3437943) is a synthetic unimolecular peptide designed to simultaneously activate three incretin and metabolic hormone receptors: the glucose-dependent insulinotropic polypeptide (GIP) receptor, the glucagon-like peptide-1 (GLP-1) receptor, and the glucagon (GCG) receptor. It is being developed by Eli Lilly and Company and is currently in Phase 3 clinical trials for the treatment of obesity, type 2 diabetes (T2D), and potentially metabolic dysfunction-associated steatotic liver disease (MASLD).
Retatrutide represents the third generation of a pharmacological lineage that began with GLP-1 receptor agonists (e.g., semaglutide, liraglutide), progressed to dual GIP/GLP-1 receptor co-agonists (tirzepatide, which received FDA approval), and now extends to triple receptor agonism by adding glucagon receptor activity. A 2024 review in Endocrinology and Metabolism (Jakubowska et al.) traced this progression and evaluated the rationale for triple agonism in the context of obesity and metabolic disease research.
Why Triple Agonism? The Rationale for Adding Glucagon Receptor Activity
Understanding retatrutide requires understanding what each receptor contributes. The scientific rationale for combining all three receptor targets is that the three hormones address complementary aspects of metabolic dysregulation in obesity and diabetes.
How do GLP-1, GIP, and glucagon receptor agonism each contribute?
GLP-1 receptor agonism reduces appetite and food intake, slows gastric emptying, and enhances glucose-dependent insulin secretion. GIP receptor agonism provides additional insulinotropic effects and may complement GLP-1 in modulating fat storage and energy homeostasis. Glucagon receptor agonism adds a distinct dimension: glucagon stimulates hepatic glucose production (relevant in fasting states), promotes fatty acid oxidation, and, critically, increases resting energy expenditure. In isolation, glucagon receptor agonism would be counterproductive in T2D due to hyperglycaemia risk. However, when co-administered with potent GLP-1 and GIP activity that suppress glucagon’s glycaemic effects, the glucagon component may contribute net metabolic benefit through enhanced thermogenesis and lipolysis.
A 2025 review in Current Cardiovascular Risk Reports (Goldney et al., University of Leicester) summarized the pharmacological rationale, noting that retatrutide is the first triple agonist with published Phase 2 data in both obesity and T2D populations, and that its glucagon receptor component is theorized to further amplify energy expenditure beyond what dual agonists achieve.
What Did the Phase 2 Retatrutide Trial in Obesity Show?
The pivotal Phase 2 obesity data for retatrutide was published in the New England Journal of Medicine in June 2023. This is the primary citation used to characterize retatrutide’s weight-reduction profile.
Key findings from Jastreboff et al., NEJM 2023 (obesity)
Jastreboff AM, Kaplan LM, Frías JP, et al. “Triple-Hormone-Receptor Agonist Retatrutide for Obesity, A Phase 2 Trial.” N Engl J Med. 2023;389(6):514–526. This was a Phase 2, double-blind, randomized, placebo-controlled trial enrolling 338 adults with a BMI of 30 or higher (or BMI 27–29 with at least one weight-related condition). Participants received once-weekly subcutaneous retatrutide at doses of 1 mg, 4 mg, 8 mg, or 12 mg, or placebo, for 48 weeks.
Key efficacy findings at 48 weeks in the trial:
- Least-squares mean body weight change: −24.2% in the 12 mg group vs. −2.1% in the placebo group
- 8 mg group: −22.8%; 4 mg group: −17.1%; 1 mg group: −8.7%
- Among participants receiving 12 mg: 100% achieved ≥5% weight loss; 93% achieved ≥10%; 83% achieved ≥15%
- Gastrointestinal adverse events (nausea, diarrhoea, vomiting, constipation) were the most common, were dose-related, and were mostly mild to moderate in severity
- Dose-dependent increases in heart rate were observed, peaking at 24 weeks and declining thereafter
Important context: These are results from a controlled Phase 2 clinical trial setting, enrolling selected participants under close clinical monitoring. They do not describe outcomes for any general population or individual, and retatrutide is not available for use outside of clinical trial contexts.
What Did the Phase 2 Retatrutide Trial in Type 2 Diabetes Show?
A second pivotal Phase 2 trial, published in The Lancet in June 2023, examined retatrutide specifically in people with type 2 diabetes.
Key findings from Rosenstock et al., Lancet 2023 (type 2 diabetes)
Rosenstock J, Frias J, Jastreboff AM, et al. “Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA.” Lancet. 2023;402(10401):529–544. This Phase 2 trial enrolled 281 adults with T2D (mean baseline HbA1c of approximately 8%), treated with diet and exercise alone or on stable metformin. Participants were randomised to receive once-weekly subcutaneous retatrutide at doses from 0.5 mg to 12 mg, placebo, or 1.5 mg dulaglutide (an approved GLP-1 receptor agonist) as an active comparator, for 36 weeks.
Key trial findings:
- Least-squares mean HbA1c change at 24 weeks: −2.02% with 12 mg retatrutide vs. −0.01% with placebo and −1.41% with 1.5 mg dulaglutide
- At 36 weeks, body weight decreased dose-dependently: −16.94% with 12 mg retatrutide vs. −3.00% with placebo and −2.02% with dulaglutide
- No severe hypoglycaemia events and no deaths were reported during the study
- Gastrointestinal adverse events were the most common side effects, consistent with the GLP-1 receptor agonist class profile
What Are the Cardiometabolic and Liver Signals in the Retatrutide Evidence Base?
Beyond primary weight and glycaemic endpoints, the Phase 2 trial data and subsequent analyses have examined other metabolic parameters.
Blood pressure and cardiometabolic parameters
A 2026 meta-analysis in the European Journal of Preventive Cardiology (Basile et al.) examined incretin-based therapies across 85 RCTs (90, 977 participants) and found that triple agonists (including retatrutide) were associated with the most pronounced systolic blood pressure reductions observed among the drug classes evaluated, a mean reduction of 6.6 mmHg systolic. These are observational meta-analytic findings that include data from the retatrutide Phase 2 trials and should be interpreted in that context.
Lipid effects and ANGPTL3/8
Post-hoc analyses of both Phase 2 retatrutide trials, published in Diabetes, Obesity & Metabolism (Wen et al., 2025), investigated retatrutide’s effects on circulating ANGPTL3/8, a protein complex involved in regulating triglyceride metabolism. Reductions in ANGPTL3/8 were observed across multiple retatrutide doses and paralleled reductions in triglycerides and LDL-cholesterol. In vitro experiments using primary human hepatocytes suggested these effects were mediated via glucagon receptor agonism. This is mechanistic post-hoc data; it does not independently demonstrate cardiovascular outcomes.
MASLD (metabolic liver disease) signals
A 2025 systematic review and meta-analysis in the Journal of Clinical Endocrinology & Metabolism (Wang et al.) evaluating GLP-1-based therapies across 25 RCTs (2, 600 patients) for MASLD/MASH found that among the agents analysed, retatrutide displayed the most pronounced reduction in liver fat content (LFC), based on imaging data from the Phase 2 trials. The authors noted this finding requires verification in dedicated Phase 3 MASLD trials. A dedicated MASLD development program for retatrutide is under investigation.
Evidence and Status Summary Table
| Domain | Status / Finding (as of mid-2026) |
|---|---|
| FDA approval status | Not approved. Investigational, Phase 3 trials ongoing |
| Mechanism | Triple agonist: GIP receptor + GLP-1 receptor + glucagon receptor |
| Phase 2 obesity RCT | Up to −24.2% mean body weight at 48 weeks (12 mg vs. placebo; NEJM 2023) |
| Phase 2 T2D RCT | HbA1c reduction up to −2.02%; body weight −16.94% at 36 weeks (Lancet 2023) |
| MASLD signal | Most pronounced liver fat reduction in GLP-1 class meta-analysis; dedicated trials ongoing |
| Phase 3 program | Ongoing, evaluating obesity, T2D, cardiovascular/renal outcomes; results pending |
| Safety profile (Phase 2) | GI adverse events most common (dose-related, mild–moderate); no severe hypoglycaemia; heart rate increases observed |
| Developer | Eli Lilly and Company (Indianapolis, IN) |
How Does Retatrutide Compare to the Existing Evidence Landscape?
Situating retatrutide within the incretin-based drug class requires honest representation of where the evidence is strong and where it remains preliminary.
A 2024 systematic review in Pharmacological Reviews (Kokkorakis et al., Beth Israel Deaconess Medical Center / Harvard Medical School) identified 53 Phase 2 and Phase 3 trials across 36 emerging anti-obesity agents. Among incretin-based therapies completing Phase 2 trials, weight loss ranged from 7.4% to 24.2%, with retatrutide’s 12 mg arm at the top of that range. The authors noted that data on mortality and obesity-related complications (including cardio-renal-metabolic events) remain needed for most emerging agents, including retatrutide.
A 2025 systematic review in the Journal of Basic and Clinical Physiology and Pharmacology (Misra et al.) pooled available clinical trial data from 691 randomised participants across three retatrutide trials, confirming that the 12 mg weekly dose showed the most significant reductions in body weight, BMI, and waist circumference, with gastrointestinal events as the primary adverse effects. The authors concluded that Phase 2 data is promising, but noted that Phase 3 confirmation, with larger populations and longer follow-up, is required before clinical adoption.
The critical limitation to state plainly: Retatrutide has no approved indication. Phase 2 trials enrol carefully selected participants under clinical supervision with defined protocols, and results do not translate directly to general use populations. Phase 3 trial data, including cardiovascular outcome data, has not been published as of mid-2026. The regulatory pathway to approval, the labelled dose, and the final risk-benefit profile are all undetermined.
Frequently Asked Questions About Retatrutide
Is retatrutide FDA approved?
No. Retatrutide (LY3437943) is not approved by the FDA for any therapeutic use. As of 2026, it is an investigational compound in ongoing Phase 3 clinical trials. It has no approved indication, no authorized dosing protocol for human use, and is not legally available as a drug or supplement. All published evidence to date is from Phase 1 and Phase 2 trial settings.
What receptors does retatrutide target?
Retatrutide is a unimolecular triple agonist that simultaneously targets the GIP receptor, the GLP-1 receptor, and the glucagon (GCG) receptor. This combination is designed to leverage complementary mechanisms: GLP-1 for satiety and glucose control, GIP for additional insulinotropic effects, and glucagon for increased energy expenditure through thermogenesis and hepatic fat metabolism.
What did the Phase 2 trial of retatrutide show in obesity?
A Phase 2 double-blind, randomized, placebo-controlled trial published in the New England Journal of Medicine in 2023 (Jastreboff et al.) reported that adults with obesity receiving 12 mg retatrutide weekly achieved a mean body weight reduction of 24.2% at 48 weeks, compared with 2.1% in the placebo group. These are results from a Phase 2 trial in a controlled research setting; retatrutide is not approved and these results do not apply to any individual or general use context.
What is the difference between retatrutide and tirzepatide?
Tirzepatide is a dual GIP/GLP-1 receptor co-agonist approved by the FDA for type 2 diabetes and obesity management. Retatrutide extends this by adding agonism at the glucagon receptor, making it a triple agonist. The glucagon component is hypothesized to further increase energy expenditure. Retatrutide is investigational and not yet approved; tirzepatide is an approved medicine with a defined clinical profile. Direct comparative Phase 3 trials between the two compounds have not been published as of mid-2026.
Investigational compound, not FDA approved. Retatrutide (LY3437943) is an investigational drug in clinical trials and is not approved by the FDA or any regulatory authority for human use. This article documents published clinical trial literature for educational and reference purposes and is not medical advice; nothing here is intended to diagnose, treat, cure, or prevent any disease, or to recommend human use of any compound. All citations link to primary sources, read them in full. Trial results apply to controlled study populations only and do not represent outcomes for any individual. Must be 21+.